155 related articles for article (PubMed ID: 35583273)
1. Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis.
Denton CP; Del Galdo F; Khanna D; Vonk MC; Chung L; Johnson SR; Varga J; Furst DE; Temple J; Zecchin C; Csomor E; Lee A; Wisniacki N; Flint SM; Reid J
Rheumatology (Oxford); 2022 Dec; 62(1):234-242. PubMed ID: 35583273
[TBL] [Abstract][Full Text] [Related]
2. In vivo affinity and target engagement in skin and blood in a first-time-in-human study of an anti-oncostatin M monoclonal antibody.
Reid J; Zamuner S; Edwards K; Rumley SA; Nevin K; Feeney M; Zecchin C; Fernando D; Wisniacki N
Br J Clin Pharmacol; 2018 Oct; 84(10):2280-2291. PubMed ID: 29900565
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials.
Choy EH; Bendit M; McAleer D; Liu F; Feeney M; Brett S; Zamuner S; Campanile A; Toso J
Arthritis Res Ther; 2013 Sep; 15(5):R132. PubMed ID: 24286335
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Khanna D; Lin CJF; Furst DE; Goldin J; Kim G; Kuwana M; Allanore Y; Matucci-Cerinic M; Distler O; Shima Y; van Laar JM; Spotswood H; Wagner B; Siegel J; Jahreis A; Denton CP;
Lancet Respir Med; 2020 Oct; 8(10):963-974. PubMed ID: 32866440
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
Schiopu E; Chatterjee S; Hsu V; Flor A; Cimbora D; Patra K; Yao W; Li J; Streicher K; McKeever K; White B; Katz E; Drappa J; Sweeny S; Herbst R
Arthritis Res Ther; 2016 Jun; 18(1):131. PubMed ID: 27267753
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
7. A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers.
Nagaraja V; Spino C; Bush E; Tsou PS; Domsic RT; Lafyatis R; Frech T; Gordon JK; Steen VD; Khanna D
Arthritis Res Ther; 2019 Sep; 21(1):202. PubMed ID: 31481106
[TBL] [Abstract][Full Text] [Related]
8. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
[TBL] [Abstract][Full Text] [Related]
9. Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Russell RJ; Chachi L; FitzGerald JM; Backer V; Olivenstein R; Titlestad IL; Ulrik CS; Harrison T; Singh D; Chaudhuri R; Leaker B; McGarvey L; Siddiqui S; Wang M; Braddock M; Nordenmark LH; Cohen D; Parikh H; Colice G; Brightling CE;
Lancet Respir Med; 2018 Jul; 6(7):499-510. PubMed ID: 29793857
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis.
Spiera R; Hummers L; Chung L; Frech TM; Domsic R; Hsu V; Furst DE; Gordon J; Mayes M; Simms R; Lafyatis R; Martyanov V; Wood T; Whitfield ML; Constantine S; Lee E; Dgetluck N; White B
Arthritis Rheumatol; 2020 Aug; 72(8):1350-1360. PubMed ID: 32336038
[TBL] [Abstract][Full Text] [Related]
11. Hit hard and early: analysing the effects of high-dose methylprednisolone on nailfold capillary changes and biomarkers in very early systemic sclerosis: study protocol for a 12-week randomised controlled trial.
van den Hombergh WMT; Kersten BE; Knaapen-Hans HKA; Thurlings RM; van der Kraan PM; van den Hoogen FHJ; Fransen J; Vonk MC
Trials; 2018 Aug; 19(1):449. PubMed ID: 30134971
[TBL] [Abstract][Full Text] [Related]
12. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
[TBL] [Abstract][Full Text] [Related]
14. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
Bigal ME; Edvinsson L; Rapoport AM; Lipton RB; Spierings EL; Diener HC; Burstein R; Loupe PS; Ma Y; Yang R; Silberstein SD
Lancet Neurol; 2015 Nov; 14(11):1091-100. PubMed ID: 26432181
[TBL] [Abstract][Full Text] [Related]
17. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S;
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801
[TBL] [Abstract][Full Text] [Related]
18. A 24-Week, Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis.
Khanna D; Denton CP; Furst DE; Mayes MD; Matucci-Cerinic M; Smith V; de Vries D; Ford P; Bauer Y; Randall MJ; Ebrahimpoor M; Kupcsik L; Stiers PJ; Deberdt L; Prasad N; Lim S; Pujuguet P; Ahmed S
Arthritis Rheumatol; 2023 Aug; 75(8):1434-1444. PubMed ID: 36787101
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.
Bigal ME; Dodick DW; Rapoport AM; Silberstein SD; Ma Y; Yang R; Loupe PS; Burstein R; Newman LC; Lipton RB
Lancet Neurol; 2015 Nov; 14(11):1081-90. PubMed ID: 26432182
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
